While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show ...

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve ...

The facility, backed by UVA, CvilleBioHub and a $4.3 million GO Virginia award, will bring lab breakthroughs to health care.

The U.S. Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related ...

AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Explore ...